Article
Washington - The optimum doses of biologic treatments for psoriasis may be higher than previously believed, according to Mark Lebwohl, M.D., professor and chairman, department of dermatology, Mt. Sinai School of Medicine.
Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
Case of Juvenile Bullous Pemphigoid with Negative Serum BP180 ELISA Test Reveals Need for Additional Testing